Sugi Predict

Sugi Predict / Compounds / SCHEMBL2174

SCHEMBL2174

SCHEMBL2174

COC(=O)[C@@H](NCc1ccc(-c2ccccc2C#N)cc1)C(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 1/20 0.45
▸ WDR5 P61964 1/20 0.45
▸ MME P08473 1/20 0.44
▸ FFAR1 O14842 1/20 0.44
▸ AKR1B1 P15121 1/20 0.44
▸ ESR2 Q92731 1/20 0.43
▸ ANPEP P15144 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ ITGB1 P05556 1/20 0.41
▸ ITGA4 P13612 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ADAM17 P78536 1/20 0.41
▸ TRPM8 Q7Z2W7 1/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ OXTR P30559 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8065614 1.00 MYC (0.45) MYCWDR5MMEFFAR1AKR1B1
SCHEMBL2432 1.00 MYC (0.45) MYCWDR5MMEFFAR1AKR1B1
Hydrochloric Acid SCHEMBL15663201 0.99 MYC (0.45) MYCWDR5MMEFFAR1AKR1B1
Hydrochloric Acid SCHEMBL3526296 0.99 MYC (0.45) MYCWDR5MMEFFAR1AKR1B1
Oxalic Acid SCHEMBL1616541 0.97 MME (0.44) MYCWDR5MMEFFAR1AKR1B1
SCHEMBL2465 0.90 MYC (0.43) MYCWDR5MMEFFAR1AKR1B1
SCHEMBL3121 0.90 MYC (0.43) MYCWDR5MMEFFAR1AKR1B1
SCHEMBL8910310 0.89 ABL1 (0.42) MYCWDR5MMEFFAR1AKR1B1
SCHEMBL14004740 0.89 FFAR1 (0.48) MYCWDR5MMEFFAR1AKR1B1
SCHEMBL2317 0.89 FFAR1 (0.48) MYCWDR5MMEFFAR1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8981109-B2 Process for the preparation of valsartan AUROBINDO PHARMA LTD (IN) 2015-03-17 — — US claimed
US-20130144067-A1 PROCESS FOR THE PREPARATION OF VALSARTAN AUROBINDO PHARMA LTD (IN) 2013-06-06 — — US claimed
WO-2012001484-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF VALSARTAN AUROBINDO PHARMA LIMITED (IN) 2012-01-05 — — WO claimed
US-7659406-B2 Process for preparing valsartan DR. REDDY'S LABORATORIES LIMITED (IN) 2010-02-09 — — US claimed
US-20060149079-A1 Process for preparing valsartan DR. REDDY'S LABORATORIES, INC. 2006-07-06 — — US claimed
WO-2023148748-A1 AN IMPROVED SAFE PROCESS FOR THE PREPARATION OF SARTAN DRUGS OF FORMULA I IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) 2023-08-10 — — WO disclosed
US-20230057675-A1 A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN HARMAN FINOCHEM LIMITED (IN) 2023-02-23 — — US disclosed
CN-110078640-B Synthesis method of valsartan intermediate 浙江美诺华药物化学有限公司 2022-04-05 — — CN disclosed
WO-2021111464-A1 A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN HARMAN FINOCHEM LIMITED (IN) 2021-06-10 — — WO disclosed
WO-2020010643-A1 METHOD FOR SYNTHESIZING VALSARTAN 浙江华海药业股份有限公司 2020-01-16 — — WO disclosed
US-8981109-B2 Process for the preparation of valsartan AUROBINDO PHARMA LTD (IN) 2015-03-17 — — US disclosed
US-8981109-B2 Process for the preparation of valsartan AUROBINDO PHARMA LTD (IN) 2015-03-17 — — US disclosed
US-20060258878-A1 chemical intermediate organic acid salt of N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine ester for hypotensive agents; treating anxiety, glaucoma and cardiovascular disorders ALEMBIC LIMITED (IN) 2006-11-16 — — US disclosed
US-20060149079-A1 Process for preparing valsartan DR. REDDY'S LABORATORIES, INC. 2006-07-06 — — US disclosed
WO-2005049587-A1 PROCESS FOR PREPARATION OF BIPHENYL TETRAZOLE RANBAXY LABORATORIES LIMITED (IN) 2005-06-02 — — WO disclosed
WO-2004101534-A1 A METHOD OF PREPARATION OF N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-y1) [1,1'-BIPHENYL] -4-y1]METHYL]-L-VALINE (VALSARTAN) ZENTIVA, A. S. (CZ) 2004-11-25 — — WO disclosed
US-5965592-A HYPOTENSIVE AGENTS NOVARTIS CORPORATION (US) 1999-10-12 — — US disclosed
EP-0443983-B1 Acyl compounds CIBA GEIGY AG (CH) 1996-02-28 — — EP disclosed
US-5399578-A Hypotensive; valsartan; high blood pressure and cardiac insufficiency CIBA-GEIGY CORP (US) 1995-03-21 — — US disclosed
EP-0443983-A1 Acyl compounds CIBA-GEIGY AG (CH) 1991-08-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230057675-A1 A PROCESS FOR THE PREPARATION OF HIGHLY PURE VALSARTAN REN, AGT, ACE MYC 2461/4885WDR5 2840/4885MME 6/4885
US-20060258878-A1 chemical intermediate organic acid salt of N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine ester for hypotensive agents; treating anxiety, glaucoma and cardiovascular disorders AGTR1, AGTR2, AGT MYC 2628/4885WDR5 4356/4885MME 233/4885
US-20130144067-A1 PROCESS FOR THE PREPARATION OF VALSARTAN TTR, VIP, VIL1 MYC 4442/4885WDR5 2459/4885MME 127/4885
US-20060149079-A1 Process for preparing valsartan PREP, TMPRSS15, REN MYC 4783/4885WDR5 2791/4885MME 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.